## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.8% below STRENGTH zone (3.0-6.0%); PEG 2.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Congress Asset Management Co. Sells 540,640 Shares of The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251222T090511 | Neutral | Relevance: 100%
- Congress Asset Management Co. significantly reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by selling 540,640 shares, decreasing its holdings by 54.4% during the third quarter. Despite this, several other institutional investors adjusted their positions, mostly increasing their stakes, while company insiders like CEO Albert G. White III and Holly R. Sheffield acquired a total of 16,230 shares. The medical device company reported strong earnings and revenue topping estimates, with analysts maintaining a "Moderate Buy" consensus rating.

**2. BD and Penn Institute Ink Collaboration to Advance Immunotherapy**
- Source: The Globe and Mail | 20251222T190827 | Somewhat-Bullish | Relevance: 59%
- Becton, Dickinson and Company (BDX) has announced a collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to advance immunotherapy. Their partnership will focus on developing a high-parameter flow cytometry panel and conducting a study involving 1,000 people to understand the human immune system and support immune-mediated treatments. This initiative aims to translate complex immune data into actionable information for clinical care, strengthening BD's position in advanced flow cytometry and single-cell analysis.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($1.04M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Analyst sentiment positive (10 raises, avg +14%). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 17.0 |
| Current P/E | 18.6 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.9% to 1.8% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.80% (CS: 79) | Neutral |
| RSI_14 | 69.9 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.121x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.84
- **Stop Loss:** $79.34 (5.4% risk)
- **Target:** $88.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 266
- **Position Value:** $22,301.44
- **Portfolio %:** 22.30%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*